Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Leaky Scanning02:28

Leaky Scanning

5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kaempferol Attenuates Spaceflight-Associated Knee Cartilage Degradation by Targeting NOX4-Mediated Mitochondrial Dysfunction.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Identification of D4 as a novel antiviral compound inhibiting hepatitis B virus surface antigen via TMEM40 upregulation.

Antiviral research·2026
Same author

Inflammatory monocytes constrain YAP-induced cell proliferation.

Science advances·2026
Same author

AI-guided analysis of human pancreatic islet sociology reveals distinct cell compositional changes in type 1 diabetes.

bioRxiv : the preprint server for biology·2026
Same author

Calpain-4 Knockdown Modulates Cholesterol Metabolism and LXRα Nuclear Localization in Experimental Alcohol-Related Liver Disease.

Alcohol, clinical & experimental research·2026
Same author

NPM1 mutation promotes creatine anabolism by FTO-dependent m<sup>6</sup>A demethylation to drive macrophage M2 polarization in acute myeloid leukemia.

Cancer letters·2026

Related Experiment Video

Updated: Jul 4, 2025

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.3K

TIM22 and TIM29 inhibit HBV replication by up-regulating SRSF1 expression.

Lin Guo1,2, Jia-Jun Liu1, Shao-Yuan Long1

  • 1Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China.

Journal of Medical Virology
|January 31, 2024
PubMed
Summary

Mitochondrial proteins TIM22 and TIM29 reduce Hepatitis B virus (HBV) replication by increasing SRSF1 expression. This finding highlights mitochondria

Keywords:
HBVSRSF1TIM22TIM29mitochondria

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.7K

Related Experiment Videos

Last Updated: Jul 4, 2025

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.3K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.7K

Area of Science:

  • Virology
  • Mitochondrial Biology
  • Immunology

Background:

  • Hepatitis B virus (HBV) infection poses a significant global health challenge.
  • Mitochondria play a crucial role in cellular antiviral responses.
  • Mitochondrial proteins are implicated in host defense against viral infections.

Purpose of the Study:

  • To investigate the role of mitochondrial proteins TIM22 and TIM29 in Hepatitis B virus (HBV) infection.
  • To elucidate the mechanism by which TIM22 and TIM29 affect HBV replication and transcription.

Main Methods:

  • Overexpression of TIM22 and TIM29 in cells infected with HBV.
  • Quantification of intracellular HBV DNA and RNA levels.
  • Measurement of secreted HBV surface antigens and E antigen.
  • Analysis of core promoter activity and SRSF1 expression.

Main Results:

  • Overexpression of TIM22 and TIM29 significantly reduced intracellular HBV DNA and RNA.
  • Secreted HBV surface antigens and E antigen levels were decreased upon TIM22 and TIM29 overexpression.
  • TIM22 and TIM29 mediated their effects by reducing core promoter activity through increased SRSF1 expression.

Conclusions:

  • TIM22 and TIM29 are critical mitochondrial components in resisting HBV infection.
  • SRSF1 acts as a suppressor of HBV replication, modulated by TIM22 and TIM29.
  • TIM22 and TIM29 represent potential therapeutic targets for treating HBV infection.